Featured
Albert Vilella highlights that SMi’s platform can be applied to a wide range of biomolecules, including proteins, nucleic acids, and small molecules, making it valuable in various fields, from drug discovery to diagnostics.
SMi describes the differences between the regulatory considerations for research use only (RUO) products and those destined for in vitro diagnostics (IVD) use, and consider how risk management can be simultaneously applied.
Single molecule imaging could be transformative for cancer biomarker detection. Here the MDC reports on foundational data from its collaboration with SMi.
Batalas features how their internal audit training course helped SMi work towards ISO 13485:2016 Quality Management System certification.
SMi has worked with ProPharma to build an ISO 13485 Quality Management System that ensures compliance to rigorous medical device standards. ProPharma Group describe what made this a huge success.
SMi Systems is developing an analytics platform that utilises advanced optics and algorithms to automate detection of single molecules within a sample. We provide an overview of computational methods and why they are so important.
Top-ranked life sciences analyst joins as SMi enters commercialisation with an instrument ready for early access customers and a focus shifting to precision engineered consumables.
Single molecule analysis could transform drug development. Both the speed and quality of this process will be dramatically improved when there is a commercial single molecule platform that can accurately measure drug properties.
SMi Systems has successfully passed the Stage 1 audit for ISO 13485 certification conducted by the British Standards Institution.
SMi Systems is developing a revolutionary benchtop instrument that probes drug interactions at single-molecule resolution. This is the story of how the groundbreaking innovation was inspired.
Accurate detection and quantification are the cornerstones of scientific and clinical research. Only the highest quality data enables informed decisions, but achieving this can conflict with time and financial constraints.
SMi reveals the foundational work that proved our capability to perform high throughput multiplexing at single molecule resolution.
SMi is delighted to continue expanding its portfolio with the granting of a second patent.
Using its single molecule detection and quantification capabilities, SMi has been contracted to develop a novel quality control assay for biologics production.
SMi announces its appointment of two new research scientists to expand its laboratory talent.
SMi is delighted to win first place in the Best New Business category.
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics.
SMi is delighted to be named as a finalist for the Best New Business award. The ceremony is due to take place on 28th September 2023.
Medicines Discovery Catapult and SMi’s CEO describe what has made their partnership so successful.
Medicines Discovery Catapult features the success of SMi’s partnerships to develop diagnostics for cancer and infectious disease.
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics.
The University of Cambridge has released a press article detailing SMi’s revolutionary diagnostic technology.
SMi has been shortlisted for two awards, ‘The One to Watch’ and ‘Medtech Company of the Year.’ The ceremony is to be held on 18th May 2023.
Medicines Discovery Catapult and SMi secure funding to validate cancer biomarker technology.
Following the award of a £1.9m grant from Innovate UK in 2021, SMi has again been successful in competing for a highly prestigious award for innovative research.
SMi has completed its first formal usability tests at the UK’s Medical Devices Testing and Evaluation Centre, located at the University Hospitals Birmingham NHS Foundation Trust.
SMi has achieved a great deal since starting its operations at the end of 2021. In addition to employing its full complement of scientists, engineers and regulatory specialists, SMi has also opened both its UK offices and US-based laboratories.
Funding unlocks strategic partnerships with the Medicines Discovery Catapult, University of Cambridge, and National Physical Laboratory.